Bassem F Salama1,2, Gregory S Korbutt3,4. 1. Department of Surgery, University of Alberta, 5.002 Li Ka Shing Bldg, 8602 112 Street, Edmonton, AB, T6G 2E1, Canada. 2. Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada. 3. Department of Surgery, University of Alberta, 5.002 Li Ka Shing Bldg, 8602 112 Street, Edmonton, AB, T6G 2E1, Canada. korbutt@ualberta.ca. 4. Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada. korbutt@ualberta.ca.
Abstract
PURPOSE OF REVIEW: Diabetes is medical and social burden affecting millions around the world. Despite intensive therapy, insulin fails to maintain adequate glucose homeostasis and often results in episodes of hypoglycemic unawareness. Islet transplantation is a propitious replacement therapy, and incremental improvements in islet isolation and immunosuppressive drugs have made this procedure a feasible option. Shortage of donors, graft loss, and toxic immunosuppressive agents are few of many hurdles against making human allogenic islet transplantation a routine procedure. RECENT FINDINGS: Xenografts-especially pig islets-offer a logical alternative source for islets. Current preclinical studies have revealed problems such as optimal islet source, zoonosis, and immune rejection. These issues are slowing clinical application. Genetically modified pigs, encapsulation devices, and new immune-suppressive regimens can confer graft protection. In addition, extrahepatic transplant sites are showing promising results. Notwithstanding few approved clinical human trials, and available data from non-human primates, recent reports indicate that porcine islets are closer to be the promising solution to cure diabetes.
PURPOSE OF REVIEW: Diabetes is medical and social burden affecting millions around the world. Despite intensive therapy, insulin fails to maintain adequate glucose homeostasis and often results in episodes of hypoglycemic unawareness. Islet transplantation is a propitious replacement therapy, and incremental improvements in islet isolation and immunosuppressive drugs have made this procedure a feasible option. Shortage of donors, graft loss, and toxic immunosuppressive agents are few of many hurdles against making human allogenic islet transplantation a routine procedure. RECENT FINDINGS: Xenografts-especially pig islets-offer a logical alternative source for islets. Current preclinical studies have revealed problems such as optimal islet source, zoonosis, and immune rejection. These issues are slowing clinical application. Genetically modified pigs, encapsulation devices, and new immune-suppressive regimens can confer graft protection. In addition, extrahepatic transplant sites are showing promising results. Notwithstanding few approved clinical human trials, and available data from non-human primates, recent reports indicate that porcine islets are closer to be the promising solution to cure diabetes.
Entities:
Keywords:
Islet xenotransplantation; Porcine islets; Type 1 diabetes
Authors: D C Brennan; H A Kopetskie; P H Sayre; R Alejandro; E Cagliero; A M J Shapiro; J S Goldstein; M R DesMarais; S Booher; P J Bianchine Journal: Am J Transplant Date: 2015-10-03 Impact factor: 8.086
Authors: P Thompson; I R Badell; M Lowe; J Cano; M Song; F Leopardi; J Avila; R Ruhil; E Strobert; G Korbutt; G Rayat; R Rajotte; N Iwakoshi; C P Larsen; A D Kirk Journal: Am J Transplant Date: 2011-08-29 Impact factor: 8.086
Authors: J S Shin; J M Kim; J S Kim; B H Min; Y H Kim; H J Kim; J Y Jang; I H Yoon; H J Kang; J Kim; E S Hwang; D G Lim; W W Lee; J Ha; K C Jung; S H Park; S J Kim; C G Park Journal: Am J Transplant Date: 2015-06-10 Impact factor: 8.086
Authors: C G Groth; O Korsgren; A Tibell; J Tollemar; E Möller; J Bolinder; J Ostman; F P Reinholt; C Hellerström; A Andersson Journal: Lancet Date: 1994-11-19 Impact factor: 79.321
Authors: Bernhard J Hering; Martin Wijkstrom; Melanie L Graham; Maria Hårdstedt; Tor C Aasheim; Tun Jie; Jeffrey D Ansite; Masahiko Nakano; Jane Cheng; Wei Li; Kathleen Moran; Uwe Christians; Colleen Finnegan; Charles D Mills; David E Sutherland; Pratima Bansal-Pakala; Michael P Murtaugh; Nicole Kirchhof; Henk-Jan Schuurman Journal: Nat Med Date: 2006-02-19 Impact factor: 53.440
Authors: Boris L Gala-Lopez; Andrew R Pepper; Rena L Pawlick; Doug O'Gorman; Tatsuya Kin; Antonio Bruni; Nasser Abualhassan; Mariusz Bral; Austin Bautista; Jocelyn E Manning Fox; Lachlan G Young; Patrick E MacDonald; A M James Shapiro Journal: Diabetes Date: 2015-11-18 Impact factor: 9.461
Authors: Frances T Lee; Anil Dangi; Sahil Shah; Melanie Burnette; Yong-Guang Yang; Allan D Kirk; Bernhard J Hering; Stephen D Miller; Xunrong Luo Journal: Am J Transplant Date: 2020-01-21 Impact factor: 8.086
Authors: Aaron A Stock; Vita Manzoli; Teresa De Toni; Maria M Abreu; Yeh-Chuin Poh; Lillian Ye; Adam Roose; Felicia W Pagliuca; Chris Thanos; Camillo Ricordi; Alice A Tomei Journal: Stem Cell Reports Date: 2019-12-12 Impact factor: 7.765